Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 19 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research

Fee For Service(FFS)

Full Time Equivalent(FTE)

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Biology Research

Structural Biology

Cell Biology

Computational Biology & Molecular Modeling

Enzymology & Molecular Interactions

Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
APIs

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Preformulation Study

Formulation Technology Research

Preparation Quality Research

Laboratory-scale Preparation Testing

Pilot-scale Preparation Testing

GMP-based Clinical Sample Production & Packaging

Formulation Stability Study

Consistency Evaluation

Analytical Method Development and Quality Control
CMC Filings
03 Preclinical Research
Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

Pharmacokinetics

In Vitro Pharmacokinetic Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings
01 One-stop Integrated Services
Pharmaceutical Research Platform
Drug Discovery Plarform
One-stop API Process R&D Department
Translational Medicine Platform
Pharmaceutical Research CDMO Service Platform
Chemical Drug Development
Medicilon's CDMO Service Platform
Preclinical Research Services
02 Key Technical Services for Drug R&D
Process Department Solid Form Screening Platform
SEND Format Conversion Platform
Flow Cytometry Technology Platform
Safety Assessment Lab of Process Chemistry
Drug Forming Research Platform
Metabolite Identification (MetID) Service Platform
Cytokine and Biomarker Detection Platform
03 Innovative Drug Services
Nucleic Acid Drug R&D Platform
Non-clinical Research for Cellular Immunotherapies
mRNA Vaccine Bioanalysis Platform
PROTAC Drug Discovery Research Platform
ADC R&D Service Platform
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
IO Pharmacodynamic Model Evaluation Platform
05 Advanced Preparation R&D
Skin Topical Preparation R&D
Ophthalmic drug R&D platform
Inhalation drug R&D platform
06 Drug Analysis
07 Public Services
CLIENT CENTER
Intellectual Property Protection
Downloads
Partnerships
Newsletters
U.S.

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2023-03-20Market Events
Join Medicilon at SAPA-GP 2023 Annual Conference

Date: 3.31-4.1 2023

Location: King of Prussia, Pennsylvania

Learn more
2023-03-14Market Events
Join Medicilon at BioTrinity 2023: Catalysing Growth in the Life Sciences Industry

Date: April 25-26, 2023

Location: Etc. venues 155 Bishopsgate, London

Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CAREERS
Talent Development
Employee Activities
Campus Recruitment
Social Recruitment
Campus Recruitment
Campus Recruitment
Social Recruitment
Social Recruitment
Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Jul 04,2022
Medicilon and Suzhou Langrui have reached a strategic collaboration
On June 19, 2022, Shanghai Medicilon Inc. and Suzhou Langrui Biomedical Co., Ltd. signed a strategic collaboration agreement on innovative drug research and development services.
More
Medicilon and Suzhou Langrui have reached a strategic collaboration
Jul 04,2022
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
On June 10, 2022, Bio-Thera Solutions, Ltd. (Bio-Thera) announced that BAT2022 for injection has obtained a clinical trial approval.
More
Medicilon assisted Bio-Thera's bispecific neutralizing antibody drug for injection BAT2022 for the treatment of new coronary pneumonia was approved for clinical use
Jul 04,2022
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug
On June 23, 2022, Shanghai Medicilon Inc.,Welman Pharmaceutical and Shenzhen Mingyu New Drug Research and Development Co., Ltd. signed a strategic collaboration on preclinical IND application services.
More
Medicilon reached the strategic collaboration on preclinical IND application services with Welman Pharmaceutical & Mingyu New Drug
Jul 04,2022
Medicilon and Xiling Lab formed a strategic partnership
On June 17, 2022, Shanghai Medicilon Inc. and Xiling Lab signed a strategic collaboration agreement on innovative drug research and development services in Tianfu Life Science Park.
More
Medicilon and Xiling Lab formed a strategic partnership
Jul 01,2022
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
On June 28, 2022, Shanghai Medicilon Inc. ("Medicilon”) and Shanghai BravoBio Co., Ltd ("BravoBio”) held an online ceremony for signing the Strategic Cooperation Agreement, which marks the two companies have officially become cooperative partners.
More
Medicilon and BravoBio held an online ceremony for signing the Strategic Cooperation Agreement
Jun 17,2022
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
​Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Jingxuan Zhang as the Vice President of the Preclinical Toxicology Research.
More
Medicilon Appoints Dr. Jingxuan Zhang as Vice President of Preclinical Toxicology Research
Jun 10,2022
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
Shanghai Medicilon Inc. (Medicilon) provided CC312 with a comprehensive preclinical study (including pharmacokinetics and safety evaluation) that complied with GLP specifications with compliant, efficient and high-quality services.
More
Medicilon Assists | China's First CD19×CD3×CD28 Trispecific Antibody Obtained FDA Implicit Approval
May 18,2022
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
Recently, Shanghai Medicilon Inc. (Medicilon, stock code: 688202.SH) announced the appointment of Dr. Jing Deng as the Vice President of the Pharmacology and Biology Department.
More
Medicilon Appoints Dr. Jing Deng as Vice President of Pharmacology, Pharmacodynamics and Biology Department
May 06,2022
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
​Recently, the State Drug Administration approved the clinical application of XNW14010, a new class 1 anti-tumor drug from Evopoint Biosciences Co., Ltd. (hereinafter referred to as "Sinovent"), which is intended for the treatment of patients with Advanced solid tumors with KRAS G12C mutation.
More
Medicilon Assist| Sinovent's New Class 1 Anti-tumor Drug XNW14010 has been Approved for Clinical Trials
May 06,2022
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
JYB1904 is a new anti-IgE recombinant humanized monoclonal antibody targeted therapy drug. IgE is the main immunoglobulin that mediates type I hypersensitivity diseases.
More
Medicilon Assistant| Jimincare's lgE Antibody Drug JYB1904 has been Approved for Clinical Trials
May 05,2022
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
Recently, Bio-Thera Solutions, Ltd. (Bio-Thera) has been approved for clinical application of BAT8006 for injection.
More
Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use
May 05,2022
Lockdown Never Stopped; Resumption of Work Increases Efficiency
On the evening of March 27, right before the lockdown, Medicilon immediately launched the emergency plan in order to maintain the regular R&D work.
More
Lockdown Never Stopped; Resumption of Work Increases Efficiency
Stock Code
688202

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->